AUTHORS
Joe Gaillard Schroers-Martin, MD, Jordan Scott Goldstein, MD, MSc2, Sunny Salazar-White, MD3, Gursharan Claire4, Arvin Eslami, MD5, John Tamaresis, PhD6, Alexandria Jensen, Phd7, Katherine Kong8, Ranjana Advani, MD9, Michael Khodadoust, MD PhD10, Neel Gupta, MD11, Lauren Maeda12, Faisal Cheema, MD13, Wen-Kai Weng, MD, PhD14, Sushma Bharadwaj, MD15, Melody Smith, MD,MS16, Mathew J. Frank, MD, PhD17, David M. Kurtz, MD, PhD18, David Miklos, MD, PhD19, Ash A. Alizadeh, MD, PhD20, Saurabh Dahiya, MD, FACP21
AFFILIATIONS
1 Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States
9 Stanford University, Stanford, California, United States
10 Stanford University, Stanford, California, United States
11 Stanford University, Stanford, California, United States
12 Stanford University, Stanford, California, United States
13 Kaiser Permanente, Santa Clara, California, United States
14 Stanford University, Stanford, California, United States
15 Stanford University, Stanford, California, United States
16 Stanford University, Stanford, California, United States
17 Stanford University, Stanford, California, United States
18 Foresight Diagnostics, Boulder, Colorado, United States
19 Stanford University, Stanford, California, United States
20 Stanford University, Stanford, California, United States
21 Stanford University, Stanford, California, United States
ABSTRACT
Background: Current end-of-treatment (EOT) assessment of large B-cell lymphoma (LBCL) via PET/CT scan has limited sensitivity and specificity for detecting low-volume residual disease. Accordingly, up to 25% of LBCL patients who respond to frontline chemoimmunotherapy (1L CIT) will subsequently relapse (Mauer et al., JCO 2014). CD19-directed autologous CAR-T therapy cures ~50% of patients in early relapse, with best outcomes consistently observed in those who have low lymphoma burden. Outcomes may be further improved by identifying LBCL patients at high risk of relapse at EOT and administering CAR-T therapy when lymphoma burden is lowest.
Lymphoma circulating tumor DNA (ctDNA) can be detected at levels <1 part per million by Phased variant Enrichment and Detection sequencing technology (PhasED-seq). EOT measurable residual disease (MRD) detected by PhasED-seq is associated with high relapse risk and an inferior 3-year progression-free survival of just 17%, with increased risk observed despite PET/CT complete response (CR) (Wang et al JCO 2025).
Rapcabtagene autoleucel (YTB323, rap-cel) is a novel CD19-directed autologous CAR-T cell therapy with a rapid manufacturing process of less than two days. With reduced time in ex vivo culture, the final product retains a greater proportion of naïve and stem cell memory T cells compared to traditional CAR-T therapies, allowing reduced cell dosage. In a phase I/II trial of patients with R/R LBCL after ≥2 prior lines of therapy, or high risk LBCL in the 1L setting, rap-cel demonstrated high response rates and low rates of grade 3/4 CRS and ICANS (NCT03960840).
Study Design and Methods: The CLEAR-1 study (CAR-T ceLL for Eradication of Active Residual disease,NCT07443137) is an investigator-initiated single-center Phase 1b clinical trial to assess the efficacy and safety of rap-cel as early MRD-directed consolidation in Large B-Cell Lymphoma (LBCL).
The trial will enroll adult patients (18+, ECOG 0-2) with histologically confirmed aggressive B-cell NHL including DLBCL, primary mediastinal LBCL, high-grade BCL with MYC and BCL2 and/or BCL6 translocations, transformed indolent lymphomas, and follicular lymphoma grade 3b. Eligible patients will have completed planned 1L CIT incorporating a CD20 monoclonal antibody and an anthracycline, with EOT PET/CT demonstrating CR or partial response (PR) that is biopsy-negative or inaccessible. Exclusion criteria include prior cellular therapy or allogeneic transplant, active central nervous system (CNS) lymphoma, history of recent stroke or transient ischemic attack, and pregnancy.
Patients with MRD detected by the CLARITY assay (Foresight/Natera, IUO) and eligible for treatment will undergo apheresis within 56 days of MRD detection, followed by lymphodepletion with fludarabine and cyclophosphamide. Patients will receive a single intravenous infusion of rap-cel at the established target dose of 12.5 x 10^6 CAR-positive T-cells. Subjects with undetectable MRD will be followed in an observational cohort for disease status and survival.
Endpoints: Primary endpoints are MRD conversion rate (detectable to undetectable) at Day 90 post-CAR-T cell infusion, and the incidence of adverse events and dose-limiting toxicities (DLTs) at Day 28 post-infusion. Secondary and exploratory endpoints include PFS at 12 months, overall survival (OS), event-free survival (EFS), modified EFS incorporating MRD status, ctDNA kinetics, and CAR-T cell expansion and persistence via flow cytometry and qPCR.
Statistics: Based on planned accrual of 20 participants in the treatment cohort, with a null hypothesis of a 17% MRD conversion rate and an anticipated alternative rate of 50%, at least 7 out of 20 patients must convert to MRD-undetectable to declare trial success, yielding a Type 1 error of 4.1% and 94.2% power. To ensure safety, continuous monitoring of toxicities via a Pocock-type sequential stopping boundary will halt accrual if DLTs exceed an acceptable 5% threshold. Futility analysis is planned after 10 evaluable participants, with the trial paused or halted if <2 participants (20%) achieve Day 90 MRD conversion.
Conclusions: By identifying MRD-detectable LBCL patients at high risk of relapse, the CLEAR-1 trial will evaluate the safety and efficacy of early consolidation with rapcabtagene autoleucel when lymphoma burden is at its lowest. The study was activated at Stanford in July 2026 and is currently open to enrollment.
DISCLOSURES
Joe Gaillard Schroers-Martin, MD: Pierre Fabre - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Navya - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony)